Xphyto Therapeutics’ (XPHY.C) subsidiary Vektor Pharma TF GmbH has finished work on their oral disintegrating film (ODF), a dosage formulation for a major European pharma-company and is now ready…
XPHY.C
Increased product efficacy and patient convenience is anticipated through faster onset of drug action, more predictable therapeutic activity and ease of use….
Xphyto and 3a are developing rapid screening tests for COVID-19 and other high-risk pandemic threats, including H1N1 (swine flu) and H5N1 (avian flu), with a specific focus on early…
Xphyto’s test may be ideal to catch the super-spreaders – the infectious carriers blithely attending drumming circles because they feel healthy….
Biotech companies especially those tackling Covid-19 are seeing incredible bumps on the boards with companies like Canadian Sona Nanotech (SONA.C), based out of Halifax, Nova Scotia, experiencing a 175%…
“Visual confirmation of test results (probe activation) was observed in five to seven minutes,” states Xphyto….
3a-Diagnostics, a diagnostic partner for Xphyto Therapeutics (XPHY.C), confirmed the functionality of the peptide biosensors working in Xphyto’s oral dissolvable thin film (ODF) platform today. 3a has developed peptide-based…
Our early coverage of Xphyto reveals the following company trait: Xphyto says, “We’re going to do this” – and then they do it – quickly….
Vektor is now proceeding with process implementation for the manufacture of Rotigotine patches for human clinical studies….
Xphyto Therapeutics’ (XPHY.C) potential deal with German brewery Oettinger Brauerei GmbH means development, production and distribution of cannabis-infused beverages for the European Market. They take their beer seriously in…